Melancholic and atypical depression as predictor and moderator of outcome in cognitive behavior therapy and pharmacotherapy for adult depression. by Cuijpers, Pim et al.
VU Research Portal
Melancholic and atypical depression as predictor and moderator of outcome in
cognitive behavior therapy and pharmacotherapy for adult depression.
Cuijpers, Pim; Weitz, E.; Lamers, F.; Penninx, B.W.; Twisk, J.; DeRubeis, R.J.; Dimidjian,




DOI (link to publisher)
10.1002/da.22580
document version
Publisher's PDF, also known as Version of record
Link to publication in VU Research Portal
citation for published version (APA)
Cuijpers, P., Weitz, E., Lamers, F., Penninx, B. W., Twisk, J., DeRubeis, R. J., Dimidjian, S., Dunlop, B. W.,
Jarrett, R. B., Segal, Z. V., & Hollon, S. D. (2017). Melancholic and atypical depression as predictor and
moderator of outcome in cognitive behavior therapy and pharmacotherapy for adult depression. Depression and
Anxiety, 34(3), 246-256. https://doi.org/10.1002/da.22580
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
E-mail address:
vuresearchportal.ub@vu.nl
Download date: 26. May. 2021
Received: 13 August 2015 Revised: 25 September 2016 Accepted: 27 September 2016
DOI: 10.1002/da.22580
R E S E A RCH ART I C L E
Melancholic and atypical depression as predictor
andmoderator of outcome in cognitive behavior therapy
and pharmacotherapy for adult depression
PimCuijpers, Ph.D.1,2 EricaWeitz, M.A.1,2 Femke Lamers, Ph.D.2,3
BrendaW. Penninx, Ph.D.2,3 Jos Twisk, Ph.D.2 Robert J. DeRubeis, Ph.D.4
SonaDimidjian, Ph.D.5 BoadieW. Dunlop,M.D., M.S.6 Robin B. Jarrett, Ph.D.7
Zindel V. Segal, Ph.D.8 StevenD. Hollon, Ph.D.9
1Department of Clinical, Neuro andDevelop-
mental Psychology, VrijeUniversiteit Amster-
dam, TheNetherlands
2EMGO Institute forHealth andCareResearch,
VUUniversity Amsterdam, Amsterdam, The
Netherlands
3Department of Psychiatry, VUUniversity
Medical Center, Amsterdam, TheNetherlands
4Department of Psychology, University of Penn-
sylvania, Philadelphia, PA, USA
5Department of Psychology andNeuroscience,
University of Colorado, Boulder, CO,USA
6Department of Psychiatry andBehavioral
Sciences, EmoryUniversity School ofMedicine,
Atlanta, GA, USA
7Department of Psychiatry, University of Texas
SouthwesternMedical Center, Dallas, TX, USA
8Department of Psychology, University of
Toronto—Scarborough, Toronto, Canada
9Department of Psychology, Vanderbilt Univer-







Background:Melancholic and atypical depression are widely thought tomoderate or predict out-
come of pharmacological and psychological treatments of adult depression, but that has not yet
been established. This study uses the data from four earlier trials comparing cognitive behav-
ior therapy (CBT) versus antidepressant medications (ADMs; and pill placebo when available) to
examine the extent to whichmelancholic and atypical depressionmoderate or predict outcome in
an “individual patient data” meta-analysis.
Methods: We conducted a systematic search for studies directly comparing CBT versus ADM,
contacted the researchers, integrated the resulting datasets from these studies into one big
dataset, and selected the studies that included melancholic or atypical depressive subtyping
according to DSM-IV criteria at baseline (n = 4, with 805 patients). After multiple imputation of
missing data at posttest, mixedmodels were used to conduct themain analyses.
Results: In noneof the analyseswasmelancholic or atypical depression found to significantlymod-
erate outcome (indicating a better or worse outcome of these patients in CBT compared to ADM;
i.e., an interaction), predict outcome independent of treatment group (i.e., amain effect), or predict
outcome within a given modality. The outcome differences between patients with melancholia or
atypical depression versus those without were consistently very small (all effect sizes g< 0.10).
Conclusions:We found no indication that melancholic or atypical depressions are significant or
relevant moderators or predictors of outcome of CBT and ADM.
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1 INTRODUCTION
Major depressive disorders are considered by many to be a heteroge-
neous condition, with many different symptoms constellations, clinical
representations, and varying levels of severity and course (Baumeister,
&Gordon, 2012). Furthermore,manydifferent psychological andphar-
macological treatments are available and effective (National Institute
for Health & Clinical Excellence [NICE], 2009), and the effects of these
treatments are very comparable, with no one treatment being much
more effective than the others (Cuijpers et al., 2016). At the same time
there are hardly any indications for which treatment is effective in a
given individual (Cuijpers et al., 2012).
Over the past few decades, several subtypes of major depressive
disorder have been proposed (Baumeister & Gordon, 2012). Subtypes
not only may help in differentiating the large group of patients with
major depression, but may also help determine whether a specific
treatment is more effective than others within one or more specific
subtypes of depression.
One important subtype of major depressive disorder is melan-
cholia (American Psychiatric Association 2013). In major depression
with melancholic features, the patient either has anhedonia or a
lack of mood reactivity, and at least three of six other symptoms
(depression that is subjectively different from grief, severe weight
loss or loss of appetite, psychomotor agitation or retardation, early
Depress Anxiety 2016; 00: 1–11 c© 2016Wiley Periodicals, Inc. 1wileyonlinelibrary.com/journal/da
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morning awakening; excessive guilt, worse mood in the morning). It
has been suggested that melancholic depression should be treated
with antidepressant medication (ADM), and that response to psy-
chotherapies in general is poor (Brown, 2007; Leventhal & Rehm,
2005).
Another important subtype of major depressive disorders that
has attracted considerable attention is atypical depression. This sub-
type is characterized by mood reactivity and two or more spe-
cific secondary symptoms (hyperphagia, hypersomnia, weight gain or
increased appetite, hypersomnia, leaden paralysis, and long-standing
interpersonal sensitivity to rejection; American Psychiatric Associa-
tion 2013; Jarrett et al., 1999; Thase, 2007).
The first observations of differential treatment response go back to
the 1950s, with atypical depression responding better to MAOIs than
TCAs (Stewart, McGrath, Quitkin, & Klein, 2007). There is evidence
suggesting that patients have preferential response tomonoamine oxi-
dase inhibitors (MAOIs) relative to tricyclic antidepressants (TCAs;
Henkel et al., 2006). Jarrett et al. (1999) showed that depressive
adults with atypical depression responded more to either cognitive
behavior therapy (CBT) or phenelzine (an MAOI) alone than to pill
placebo. The response to the two active modalities did not differ.
It is unclear what other psychotherapies or other medications, if
any, should be preferred or avoided in these patients (Stewart et al.,
2007).
Although the hypothesis that diagnostic subtypes such as melan-
cholic and atypical depressive moderate or predict treatment out-
comes is popular, few studies exist to test it. An important reason for
this void is that most trials focus on patients with major depression
in general and are only powered to determine whether treatment is
effective in the overall patient group. Few studies have been designed
to examine whether a clinical characteristic, such as a diagnosis of
a melancholic or atypical depressive subtype, moderates outcome
(Cuijpers et al., 2012; Uher et al., 2011); and secondary analyses of tri-
als typically do not have sufficient statistical power to identify signifi-
cant moderators (Brookes et al., 2004).
In the current “individual patient data” (IPD) meta-analysis, we
pooled the data from four randomized trials examining melancholia
and atypical depressive subtypes asmoderators and predictors of out-
come in trials comparing CBT versus ADM and also included data
regarding response to pill placebo if the trial contained one. Modera-
tors indicate whether certain subsets of participants respond better to
one treatment than to another (examined in trials in which two treat-
ments are directly compared with each other; in our case CBT and
ADM). In these data, we also can examine melancholia and atypical
depression as nonspecific predictors, which indicatewhether these char-
acteristics are related to improvement, regardless of comparison or
control groups (commonwithin-group improvement). Because we also
included some studies in which CBT and ADM were compared with
a pill placebo, we also could examine whether melancholia and atypi-
cal depression are specific predictors, and predict specificity of response
(the extent to which melancholia and atypical depression predict
change over and above what is produced simply by going into generic
treatment).
2 METHODS
2.1 Identification and inclusion of studies
The methods for this “IPD” meta-analysis have been reported
elsewhere (Cuijpers et al., 2014b). To identify potential studies
for inclusion, we turned to an existing database of trials on the
psychological treatment of adult depression, which also includes all
trials directly comparing psychological treatments and ADM. This
database has beendescribed in detail elsewhere (Cuijpers, van Straten,
Warmerdam,&Andersson, 2008), and has been used in a series of pub-
lished meta-analyses (www.evidencebasedpsychotherapies.org). This
database has been continuously updated through comprehensive lit-
erature searches (through January 2014) and the update is used here.
Abstracts were identified by combining terms indicative of psycholog-
ical treatment and depression (both MeSH terms and text words). For
this database, we also checked the primary studies from earlier meta-
analyses of psychological treatment for depression to ensure that no
published studies weremissed.
For the current study, we included (a) randomized controlled tri-
als in which (b) CBT (c) was compared with ADM (d) for patients with
a depressive disorder, (e) based on an established standardized diag-
nostic interview, and (f) in which atypical or melancholic depression
according to one of the versions of theDSMwasmeasured.We consid-
eredapsychological intervention tobeCBTwhencognitive restructur-
ingwas the core component of the treatment for adults (Cuijpers et al.,
2013b). We excluded studies in children or adolescents (<18 years).
Studies specifically aimed at depressed patientswith comorbid general
medical or psychiatric disorders were included.
After identifying potential trials for inclusion, the corresponding
authors of each were contacted by e-mail and invited to participate in
this project byproviding thedata from their trials, including depression
scores pre- and posttreatment, and the sociodemographic and clini-
cal characteristics of participants. When the authors did not respond
within 2 weeks, we sent a reminder. If no answer was received to that
reminder, we considered the trial unavailable.
2.2 Quality assessment and data extraction
We assessed the quality of the 24 trials comparing CBT versus ADM
using four criteria of the “Risk of bias” assessment tool, developed
by the Cochrane Collaboration (Higgins, & Altman, 2008). This tool
assesses possible sources of bias in randomized trials, including the
adequate generation of allocation sequence, the concealment of allo-
cation to conditions, the prevention of knowledge of the allocated
intervention (masking of assessors), and dealing with incomplete out-
come data (this was assessed as positive when intention-to-treat anal-
yses were conducted, meaning that all randomized patients were
included in the analyses).
In the assessment of trial quality, we only used the data reported
in the published papers (and not the information provided by the par-
ticipating authors), because we considered this to be the most conser-
vative estimate. Because we also tested whether the studies included
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in the IPD meta-analysis differed from the studies that did not partic-
ipate, personal information from the participating authors also might
lead to differences between those studies included and those studies
not included.
We also coded additional aspects of the included studies, including
participant characteristics, aspects of the CBT and the type of ADM,
and trial characteristics. Two independent researchers conducted the
quality assessments and data extraction.
2.3 Differences between included and not-included
studies in the IPDmeta-analysis
In order to examine whether the studies from which the primary
data were included in the IPD meta-analysis differed from the other
studies, we first calculated the effect sizes indicating the difference
between CBT versus ADM at posttest based on the data reported
in the published papers. We calculated effect sizes by subtracting
(at posttest) the average score of the CBT group from the average
score of the ADM group, and dividing the result by the pooled stan-
dard deviation. Because several studies had small samples, we cor-
rected the effect size for small sample bias according to the proce-
dures suggested by Hedges and Olkin (Hedges’ g; Hedges, & Olkin,
1985).
In the calculations of effect sizes, we focused mainly on the
HAM-D-17 as outcome instrument. If only dichotomous outcomes
for the HAM-D-17 were reported without means and standard devi-
ations, we used the procedures described by Borenstein, Hedges,
Higgins, and Rothstein (2009) to calculate the standardized mean
difference.
Then we conducted a univariate metaregression analysis with the
effect size (based on the published data) as the dependent variable,
and as the predictor a dummy variable indicating whether or not the
primary data were included in the IPD meta-analysis. These anal-
yses were conducted using Comprehensive Meta-analysis software
(version 2.2.057).
Publication bias was tested in the full set of studies meeting inclu-
sion criteria and also separately in the set of studies thatwere included
in the IPD meta-analyses. This was done by inspecting the funnel plot
on primary outcomemeasures and byDuval and Tweedie’s (2000) trim
and fill procedure that yields an estimate of the effect size after publi-
cation bias has been taken into account (as implemented in Compre-
hensive Meta-Analysis, version 2.2.021). We also conducted Egger’s
test of the intercept to quantify the bias captured by the funnel plot
and test whether it was significant.
2.4 Missing data
In the IPD dataset, we first imputed missing depression scores at
posttest with a multivariate imputation algorithm (“mi impute mvn,”
in Stata MP 13.1 for Mac). In this multiple imputation method, sev-
eral datasets are generated, and the analyses are conducted separately
in each dataset, after which the results are combined into one out-
come. Multiple imputations are currently considered to be the most
sophisticated method for handling missing data in randomized trials
(Donders, van der Heiden, Stijnen, & Moons, 2012). We generated
100 new datasets with the observed and imputed scores for posttest
depression scores from trial, depression score at baseline, age, gender,
and time from baseline to follow-up.
2.5 IPDmeta-analyses
We first examined baseline differences between patients with melan-
cholia or atypical depression and patients not meeting criteria for a
subtype.We examined differences in baseline depression and sociode-
mographics, while accounting for clustering of patients within stud-
ies.Weconductedmultilevelmixed-effects logistic regression analyses
with the dummy variables of the subtypes (melancholic vs. not; atypi-
cal vs. not) as dependent variables and the baseline characteristics as
predictors.
In order to examine the extent to which melancholia and atyp-
ical depression moderated outcome, we conducted a series of so-
called “one-step” IPD meta-analyses (Riley, Lambert, & Abo-Zaid,
2010). In these analyses, a mixed effects model is used to exam-
ine whether a moderator or predictor is associated with the out-
come, while accounting for clustering of patients within studies. One-
step IPD meta-analyses allow for the most sophisticated modeling
of covariates. It affords greater power and is less affected by bias
than the “two-step” IPD meta-analyses, in which IPD are used to
estimate the treatment–moderator interaction within each trial, fol-
lowed by a standard inverse variance meta-analysis (Bower et al.,
2013).
In the first series of main analysis, we examined whether melan-
cholic and atypical depression moderated outcome, looking for differ-
ential outcomes for CBT relative to ADM in patients with or with-
out melancholia and in patients with or without atypical depression. In
these analyses, we used the (imputed) posttest HAM-D-17 scores as
the dependent variable. As predictors, we used the baseline HAM-D-
17 scores, the treatment dummy (CBT = 1 and ADM = 0), melancho-
lia/atypical (yes/no), and the interaction betweenmelancholia/atypical
and the treatmentdummy,while adjusting for the clusteringof patients
within studies.
In addition, we performed the same analysis adjusted for other
sociodemographic indices that were available in the majority of stud-
ies (age, gender, minority status, married or not, more than 12 years
of education or less), trial characteristics (type of ADM; whether or
not the trial was conducted in the United States), the preceding four
quality criteria for each trial as predictors in the model, and time to
follow-up.
We also conducted the same analysis for the trial completers
only (the patients for whom posttest data were available, so not the
intention-to-treat sample).
In the second series of analyses, we examined whether melancho-
lia/atypical features were nonspecific predictors of outcome, by exam-
ining whether melancholia/atypical features were associated with the
posttestHAM-D-17 scorewithin theCBTgroup, and separately,within
the ADM group. In these analyses, posttest HAM-D-17 score was
again used as the dependent variable and melancholia and atypical
depression, as well as baseline HAM-D-17 scores, were entered into
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F IGURE 1 Flowchart of inclusion of studies
the model as predictors. We then repeated the analyses adjusted for
the sociodemographics indices and the four trial quality criteria previ-
ously described, alongwithmelancholia/atypical features and baseline
HAM-D-17 scores. These analyses were repeated once more with the
completers only.
In the third series of analyses, we examined whether melancho-
lia/atypical features predicted specificity of response (was a specific
predictor), through examining whether melancholia/atypical features
predicted differential outcome for CBT compared to pill placebo
controls, and separately for ADM compared to pill placebo con-
trols (Such specific prediction is a special case of moderation vis-à-
vis nonspecific factors common to all treatments.) Again, we used
posttest HAM-D-17 scores as the dependent variable, and baseline
HAM-D-17 scores as the treatment dummy (CBT vs. pill placebo;
and separately, ADM vs. pill placebo) melancholia/atypical features,
and melancholia/atypical by treatment interaction as predictors.
This same model was analyzed again adjusting for the sociodemo-
graphics, trial characteristics, and quality criteria, along with melan-
cholia/atypical features, and then repeated again with completers
only.
3 RESULTS
3.1 Selection of studies
Of the 1,613 full-text papers retrieved, 1,589 were excluded (details
are given in Fig. 1). Twenty-three studies met inclusion criteria for the
current meta-analysis (see also our earlier reports on this IPD meta-
analyses). One other study was only aimed at patients with atypical
depression and was not included in the current set of studies, because
only nonatypical patients were included and comparisons with other
patients were therefore impossible (Jarrett et al., 1999). Of these 23
studies, 16 provided patient-level data (70%). Four studies of those
16 studies collected data on the presence of melancholia and atypi-
cal depression, as well as on baseline and posttest depression scores
using the HAM-D-17 (DeRubeis et al., 2005; Dimidjian et al., 2006;
Dunlop et al., 2012; Segal et al., 2006). In a previous meta-analysis, we
identified five studies in which CBT was compared with pill placebo
(Cuijpers et al., 2014a). Two of these (40%) also provided data on
melancholia and atypical depression (DeRubeis et al., 2005; Dimidjian
et al., 2006).
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The four studies included 805 patients, 402 in the ADM conditions,
290 in the CBT conditions, and 113 in the pill placebo conditions. Of
these 805 patients, 298 met criteria for melancholia (37.0%), 140 had
atypical depression (17.4%), and 367 did not meet criteria for either
subtype (45.6%). Sixteenpatientsmet criteria forbothmelancholia and
atypical depression, but because one of the criteria for atypical depres-
sion is that the criteria for melancholia are not met at the same time,
these patients were considered to have only melancholia and included
in the 37.0% above.
3.2 Characteristics of included studies
In all the four included studies, patients were recruited (in part)
through the community, all were aimed at adults in general (none
at specific populations). Three studies were conducted in the United
States, one inCanada.All four studies usedan selective serotonin reup-
take inhibitor as ADM, definedmajor depressive disorder according to
the DSM-IV, and applied CBT in an individual treatment format. The
number of treatment sessions in CBT varied from 16 to 28.
The quality of the included studies based on the published reports
varied (Table 1). Two of the four studies reported an adequate
sequence generation and one reported allocation to conditions by an
independent (third) party. Three studies reported blinding of outcome
assessors, and in three studies intention-to-treat analyses were con-
ducted. One study met all four of the quality criteria, two others met
two or three criteria; and the remaining study had a lower quality (0 of
the four criteria).
3.3 Available and unavailable data
We compared the four studies from which the primary data were
included in the current IPD meta-analysis study with the 19 trials
that met our inclusion criteria, but which did not contribute their pri-
mary data to the current study (11 studies did provide data, but had
not measured melancholic and atypical subtypes). We calculated the
effect sizes from all published studies and pooled them. The results
for the included studies and the nonincluded studies are presented in
Figure 2. We found no significant difference between the 19 studies
that did not contribute primary data to the current meta-analysis and
the four studies that were included (P= .47).
For all 23 studies meeting our inclusion criteria, as well as for the
subgroupof four studies included in the IPDmeta-analysis and the sub-
group of 19 studies not included in the IPDmeta-analysis, we found no
indicationof publicationbias. For all three groupsof studies,Duvall and
Tweedie’s trim and fill procedure suggested that no trials weremissing
and that the adjusted effect sizewas identical to the unadjusted effects
size. Egger’s test of the intercept also did neither point at significant
publication bias in the total group of studies, nor in the included and
not-included studies (P> .1).
3.4 Baseline differences between patients with
melancholia or atypical depression and other patients
We compared patients with melancholia to all other patients (includ-
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F IGURE 2 Direct comparisons of CBT and ADM for adult depression: Hedges’ g of studies providing data and those not providing primary data














19.88 (0.64)b - 0.12 0.02*** −0.07 0.02** 0.11 0.02*** −0.03 0.03
Age (M [SE]) 39.67 (0.95)b - −0.00 0.01 0.01 0.01 0.00 0.01 0.01 0.01
Female gender 483/805 60.0 −0.22 0.16 0.20 0.20 −0.20 0.17 0.10 0.22
Married 295/800 36.9 0.14 0.16 −0.23 0.21 0.04 0.18 −0.20 0.22
>12 Years education 627/773 81.1 0.25 0.22 −0.01 0.26 0.31 0.23 0.17 0.27
Minority status 174/631 21.6 −0.16 0.20 0.42 0.22 o −0.06 0.21 0.47 0.25o
Employed 288/781 36.9 −0.16 0.60 0.10 0.20 −0.04 0.19 0.06 0.23
oP< .1; *P< .05; **P< .001.
aAll analyses were done separately for each variable in univariate analyses and with all variables together in multivariate analyses. Only the results for the
multivariate analyses are presentedhere. Theonly difference in termsof significant findingswas thatminority statuswas significant (P< .05) in theunivariate
and not significant (P < .1) in the multivariate analyses comparing atypical to all other patients, while there was only a trend in the multivariate analyses
(P< .1).
bAll categorical variables are coded as 1 (having that characteristics such as female gender, or beingmarried) or 0 (not having this characteristic), andmelan-
cholia and atypical depression are also coded as 1 (melancholia/atypical depression present) or 0 (not present).
not meet criteria for atypical depression for baseline depression and
sociodemographic variables. We did the same analyses for atypi-
cal depression. The results are presented in Table 2. We found that
patients with melancholia were significantly more depressed at base-
line than other patients (P < .001). Patients with atypical depression
were significantly less depressed than other patients (P < .01), but
when the melancholia patients were excluded from the analyses, the
difference was no longer significant (Table 2). No other variable was
significant, except that minority status was significantly associated
with havingmelancholic depression in the univariate analyses (P< .05).
In the multivariate analyses this association was no longer significant,
although there was a trend (P< .1).
The effect size indicating the difference between patients with
melancholic depression and those not meeting criteria for a subtype
at baseline was g = 0.40 (95% CI: 0.23∼0.57), which corresponds
with 1.48 points difference on the HAM-D-17 (95% CI: 0.85∼2.11).
The effect size indicating the difference between patients with
atypical depression and those with no subtype was g = −0.13 (95% CI:
−0.40∼0.14), or 0.51 points on the HAM-D-17 (95%CI:−1.49∼0.46).
3.5 Melancholia asmoderator of outcome in CBT
versus ADM
The results of the mixed effects models are presented in Table 3. As
canbe seen, noneof the analyses showed thatmelancholia significantly
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TABLE 3 Melancholic depression as predictor andmoderator of outcome in studies comparingCBTwithADM for adult depression: HAM-D-17
Intention to Treat (itt) Adjusted (itt)b Completers Only
Melancholia As Coefficient SE p Coefficient SE p Coefficient SE p
Moderator of CBT versus PHAa (N= 703) (N= 652) (N= 443)
Baseline HAM-D 0.24 0.07 <.001 0.25 0.07 <.001 0.25 0.07 <.001
CBT versus pharmacotherapy 0.12 0.62 .85 0.13 0.63 .83 0.36 0.66 .59
Melancholic depression 0.08 0.68 .90 −0.05 0.70 .94 0.06 0.72 .93
Melancholic× treatment −0.42 1.12 .71 −0.38 1.13 .74 −0.25 1.17 .83
Constant 2.86 1.39 .04 1.65 2.05 .34 2.71 1.41 .06
Predictor of improvement within CBT (N= 295) (N= 277) (N= 171)
Baseline HAM-D 0.29 0.10 .004 0.29 0.10 .005 0.33 0.11 .002
Melancholic depression −0.29 0.86 .74 −0.32 0.87 .71 −0.10 0.92 .91
Constant 2.26 2.06 .27 2.00 3.19 .53 1.54 2.22 .49
Predictor of improvement within PHA (N= 408) (N= 375) (N= 272)
Baseline HAM-D 0.22 0.09 .01 0.23 0.09 .01 0.19 0.09 .03
Melancholic depression 0.13 0.69 .86 −0.01 0.71 .99 0.23 0.74 .76
Constant 3.22 1.73 .06 1.35 2.69 .62 3.69 1.75 .04
Predictor of CBT comparedwith pill placebo (N= 217) (N= 196) (N= 176)
Baseline HAM-D 0.40 0.10 <.001 0.42 0.12 <.001 0.42 0.10 <.001
CBT versus Pill placebo −1.98 1.03 .06 −1.73 1.50 .12 −2.21 1.04 .03
Melancholic depression −1.06 1.29 .41 −1.58 1.36 .25 1.08 1.29 .40
Melancholic× treatment 0.96 1.88 .61 1.14 1.97 .56 0.90 1.86 .63
Constant 5.40 2.19 .01 1.94 3.66 .60 5.25 2.16 .02
Predictor of PHA comparedwith pill placebo (N= 333) (N= 293) (N= 266)
Baseline HAM-D 0.33 0.09 .001 0.38 0.10 <.001 0.31 0.09 .001
Pharmacotherapy versus pill placebo −2.31 0.95 .02 −2.52 0.95 .01 −2.74 0.97 .01
Melancholic depression −0.93 1.38 .50 −1.57 1.39 .26 −0.97 1.42 .50
Melancholic× treatment 0.54 1.75 .76 1.30 1.77 .46 0.42 1.79 .81
Constant 6.78 1.97 .001 0.94 3.15 .77 7.42 1.96 <.001
aCBT= 1; ADM is 0.
bAdjusted for sociodemographics (gender, minority status, married or not, more than 12 years of education or less) and the four quality criteria for each trial.
F IGURE 3 Interaction between melancholia and nonmelancholia in
CBT and ADM
moderated outcome of CBT versus ADM. The interaction between
melancholia and nonmelancholia in CBT and ADM is presented in
Figure3.As canbe seen,ADMwasa littlemoreeffective inmelancholic
patients compared to CBT, but that did not approach significance.
We also found no evidence that melancholia was a nonspecific pre-
dictor of outcome (melancholia was not significantly associated with
improvement or the lack of same within the CBT group or within the
ADMgroup). Finally, we found no evidence thatmelancholiawas a spe-
cific predictor, as it did not significantly predict differential response
for either CBT or ADM compared to pill placebo controls.
We conducted a series of sensitivity analyses. First, we ran the anal-
yses comparing CBT and ADM one more time while leaving out the
baseline depression score on the HAM-D-17. Second, we ran the anal-
yses comparing CBT and ADM four more times, leaving out one of the
studies in each of the analyses. Third, we selected the patients with
melancholic depression and examined within that group whether CBT
and ADM resulted in differential outcomes. Fourth, we excluded the
patients with atypical depression, so that we directly compared those
withmelancholia and those notmeeting criteria for a subtype. Because
the mixed model may not estimate the random intercept correctly, we
added three dummy variables for each of the studies (the fourth study
was used as reference group) to the model, but again found very com-
parable outcomes (results not reported in the tables). We also ran the
analyses separately for eachof the studies.Noneof theseanalyses indi-
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TABLE 4 Atypical depression as predictor andmoderator of outcome in studies comparing CBTwith ADM for adult depression: HAM-D-17
Intention to Treat (itt) Adjusted (itt)b Completers Only
Model: Atypical As Coefficient SE p Coefficient SE p Coefficient SE p
Moderator of CBT versus PHAa (N= 692) (N= 641) (N= 436)
Baseline HAM-D 0.25 0.07 <.001 0.26 0.07 <.001 0.27 0.07 <.001
CBT versus pharmacotherapy 0.25 0.59 .67 0.34 0.61 .57 0.85 0.62 .17
Atypical depression 0.90 0.80 .27 1.14 0.83 .17 1.31 0.84 .11
Atypical × treatment −1.55 1.25 .21 −1.83 1.28 .15 −2.71 1.37 .048
Constant 2.52 1.44 .08 1.12 2.07 .59 1.91 1.45 .19
Predictor of improvement within CBT (N= 290) (N= 272) (N= 169)
Baseline HAM-D 0.29 0.10 .004 0.29 0.10 .005 0.35 0.11 .001
Atypical depression −0.65 0.93 .48 −0.49 0.96 .61 −1.38 1.06 .19
Constant 2.22 2.05 .28 1.80 3.17 .57 1.41 2.17 .52
Predictor of improvement within PHA (N= 402) (N= 369) (N= 267)
Baseline HAM-D 0.22 0.09 .01 0.24 0.09 .009 0.22 0.09 .01
Atypical depression 0.94 0.88 .28 1.33 0.88 .13 1.44 0.91 .12
Constant 2.99 1.78 .09 0.80 2.75 .77 2.96 1.84 .11
Predictor of CBT comparedwith pill placebo (N= 217) (N= 196) (N= 176)
Baseline HAM-D 0.38 0.10 <.001 0.38 0.11 <.001 0.42 0.10 <.001
CBT versus Pill placebo −1.55 0.95 .10 −1.36 0.99 .17 −1.96 0.93 .04
Atypical depression 1.53 1.58 .33 1.73 1.64 .29 1.28 1.57 .41
Atypical × treatment 0.04 2.42 .99 0.45 2.52 .86 0.81 2.42 .74
Constant 5.01 2.23 .03 2.04 3.63 .57 4.71 2.18 .03
Predictor of PHA comparedwith pill placebo (N= 333) (N= 293) (N= 266)
Baseline HAM-D 0.31 0.09 .001 0.35 0.10 <.001 0.31 0.09 .001
Pharmacotherapy versus pill placebo −1.83 0.87 .04 −1.64 0.87 .06 −2.27 0.89 .01
Atypical depression 1.36 1.70 .43 1.30 1.68 .44 1.14 1.74 .51
Atypical × treatment −1.71 2.10 .41 −2.48 2.10 .24 −1.74 2.16 .41
Constant 6.54 2.01 .001 0.70 3.10 .82 6.87 1.98 .001
aCBT=1; ADM is 0.
bAdjusted for sociodemographics (gender, minority status, married or not, more than 12 years of education or less) and the four quality criteria for each trial.
cated thatmelancholiawas a significantmoderator of outcome forCBT
and ADM (P> .1 for all analyses).
Three of the four studies also used the Beck Depression Inventory-
II (BDI-II) as an outcome instrument. We imputed missing scores at
posttest and examined whether the BDI-II was a moderator of out-
come, but again no significant association was found (P> .1).
3.6 Atypical depression asmoderator of outcome in
CBT versus ADM
The results of atypical depression as amoderator, nonspecific and spe-
cific predictor of outcome inCBTandADMare presented in Table 4. As
can be seen, we found no evidence that atypical depression is a signifi-
cantmoderator, specificpredictor, or nonspecificpredictorof outcome.
The interaction between atypical depression and other depressive dis-
orders across CBT and ADM is presented in Figure 4. As can be seen,
ADM was a little more effective in patients with atypical depression
compared to CBT (but this was not significant).
F IGURE 4 Interaction between atypical depression and no atypical
depression in CBT and ADM
We only found one significant outcome, indicating that the
interaction between atypical depression and the treatment dummy
was significant in the completers sample (patients with atypi-
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TABLE 5 Differences between patientswith andwithoutmelancholic or atypical depression for posttestHAM-D-17:within and between group
effect sizes (Hedges’ g) and differences in meansa







Atypical Depression versus Other
Patients (Melancholia Excl.)
Hedges’ gc
• CBT 4 −0.09 −0.43∼0.25 .60 −0.08 −0.37∼0.20 .56 0.02 −0.29∼0.33 .91
• ADM 4 0.09 −0.11∼0.29 .39 0.06 −0.19∼0.31 .63 0.15 −0.13∼0.43 .29
• Pill placebo 2 −0.04 −0.43∼0.34 .83 0.09 −0.42∼0.60 .73 0.09 −0.45∼0.63 .73
Difference inmeansd
• CBT 4 −0.62 −2.88∼1.64 .59 −0.62 −2.60∼1.36 .54 0.14 −1.93∼2.21 .89
• ADM 4 0.59 −0.74∼1.91 .38 0.40 −1.27∼2.06 .64 0.97 −0.82∼2.76 .29
• Pill placebo 2 −0.33 −3.12∼2.47 .82 0.64 −3.10∼4.38 .74 0.65 −3.14∼4.43 .74
Within diagnostic
groupse
Within group of patients with
melancholia
Within group of patients with
atypical depression





4 0.12 −0.14∼0.38 .36 0.12 −0.22∼0.46 .48 0.13 −0.23∼0.48 .48
• CBT versus pill
placebo
2 1.00 0.45∼1.56 .00 0.80 0.17∼1.43 .01 0.77 0.13∼1.40 .02
• ADMversus pill
placebo





4 0.85 −0.96∼2.66 .36 0.82 −1.37∼3.01 .46 0.87 −1.43∼3.16 .46
• CBT versus pill
placebo
2 7.29 3.53∼11.05 .00 5.61 1.35∼9.87 .01 5.46 1.10∼9.82 .01
• ADMversus pill
placebo
2 4.96 2.10∼7.83 .00 5.38 1.55∼9.20 .01 5.41 1.52∼9.30 .01
aThese effect sizes indicate the difference within each of the conditions, between those with and those without a depressive subtype.
bNumber of studies.
cLower score inmelancholic/atypical depression indicates a negative effect.
dThe difference inmeans indicates the difference betweenmen andwomenwithin each condition in HAM-D-17 score.
eThese effect sizes indicate the difference between conditions within the group of patients with a specific subtype of depression
fA positive effect indicates that CBT is superior to ADM.
cal depression responding better to ADM). However, because the
P-value was just below the 0.05 threshold (P = .048) despite
the large sample, and because the number of analyses we con-
ducted was considerable, this finding should be considered with
caution.
We ran the same sensitivity analyses as we did for melancholic
depression, as well as the analyses with the BDI-II as outcome, but
again found no indication that atypical depression is a moderator of
outcome.
3.7 Effect sizes indicating the differences between
melancholic and atypical depression
In order to examine the size of the difference between those with
melancholia and those without at posttest, we calculated the effect
sizes indicating these differences within each of the condition (sepa-
rately for the groups receiving CBT, ADM, and pill placebo; Table 5).
We also calculated the differences between CBT and ADMwithin the
group of patients with melancholia, as well the differences between
CBT and placebo and ADM and placebo. We calculated standardized
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effect sizes (Hedges’ g) as well as differences in means (indicating the
difference in scores on the HAM-D-17).
As can be seen, all effect sizes indicating the difference between
thosewith andwithoutmelancholiawere smaller than g=0.10 and not
significant (P> .1) in all three treatment groups, the effect size indicat-
ing the difference between CBT and ADMwithin melancholia patients
was also small (g = 0.12) and the difference between CBT and ADM
compared to placebowere both large and significant.
In the same way, we calculated the effect sizes for atypical depres-
sion and again found few small effects for the within condition
effect sizes, as well as small differential effects for CBT versus ADM
within this group, and large effects of both conditions versus placebo
(Table 5). Because these outcomes may be affected by patients with
melancholia (who were more depressed at baseline and could also
be more depressed at posttest), we also calculated these effect sizes,
while excluding melancholic patients, and again found comparable
results.
4 DISCUSSION
We integrated the data of four randomized trials comparing CBT
and ADM with or without a pill placebo condition and examined the
extent towhichmelancholic andatypical depressionmoderatedorpre-
dicted outcome within or between modalities. None of the analyses
showed that melancholic or atypical depressive subtypes were a sig-
nificant moderator of outcome, a nonspecific or a specific predictor.
The posttest differences between patients with melancholia or atyp-
ical depression and those without were very small. We did find that
severity was significantly higher in melancholic patients at baseline,
butwe did not find thatmelancholiawas amoderator of outcome, even
whenwe did not adjust for baseline severity of depression.
These results may appear surprising since there is increasing evi-
dence that the melancholic and atypical depressive subtypes not
only differ in symptom presentation, but also in biological correlates
and somatic consequences (Lamers et al., 2013; Penninx, Milaneschi,
Lamers, & Vogelzangs, 2013). Inflammatory and metabolic dysregula-
tion have been found to be more pronounced in atypical depression,
while HPA-axis hyperactivity is stronger in melancholic depression.
There also is evidence that the determinants of the long-term course
ofmelancholic and atypical depression differ fromeach other and from
other depressive disorders (Lamers et al., 2012).
Since our study did not find any indication, however, that melan-
cholic and atypical depression were moderators or predictors of out-
come, the findings are in line with the hypothesis that both treatment
modalities include effective mechanisms, which could influence the
biopsychosocial systems similarly or differentially. The distinct sub-
types of depressionmay have different etiologies and course of illness,
but our findings suggest that the effects of CBT and ADM do not dif-
fer, nor does eithermodality work better or worse in these subtypes. It
is possible that when the exact processes leading to depression and its
subtypes areunderstood,more focused treatments,with knownmech-
anisms, can be developed that focus on the core elements underlying
these processes.
This analysis has several important strengths and limitations that
have to be considered. Strengths include the relatively high statisti-
cal power, related to the large sample size, and that the analyses were
conducted in a uniform way across all included studies. There are also
some limitations, however. We could include only a relatively small
number of studies, and most studies either did not provide primary
data or no data on melancholic or atypical depression were collected
in the study. It is possible that our selection was not representative
of all available studies in this field. Another limitation is that it is not
clear whether melancholic and atypical depression are valid diagnos-
tic subtypes and whether they were diagnosed appropriately in the
studies, despite the fact that it was measured in all studies accord-
ing the DSM criteria. Furthermore, the quality of the included stud-
ies as reported in the published papers was not consistently optimal
(althoughmost quality ratingswould havebeenpositive after receiving
additional information from the authors). The studies also varied from
each other in terms of type of antidepressant, maximal dose, average
dose, and duration of treatment, and it was not possible to categorize
this in a uniform way. It also was not possible to categorize the deliv-
ery of CBT in a uniformway. Amore general limitation of these studies
is that patients cannot be blinded when randomized to psychotherapy,
which may result in bias in favor of psychotherapy. A final limitation is
that we only examined short-term outcomes, while there are indica-
tions that CBT has enduring effects that are clearly detectable up to
1 year after treatment (Cuijpers et al., 2013a).
Adults with atypical depression can be optimal candidates for effi-
cient CBT because their reactive mood maps right onto the mood
shifts, which trigger application of the cognitive model. On the other
hand, the unreactive mood, anhedonia, and psychomotor retardation
that are cardinal features of melancholic depression can make CBT
laborious for both patients and clinicians, which can prompt consider-
ing the benefits of using ADM before CBT, switching to ADM if CBT is
inefficient or adding ADM to CBT. The data we provide do not speak
to clinical efficiency, patient or clinician preferences, or other impor-
tant process relevant to daily functioning in patient and clinicians’
lives.
Despite these limitations, the finding that neither melancholic nor
atypical depression was found to be significant moderator or predic-
tor of outcome between or within CBT versus ADM is important from
a clinical as well as a scientific perspective. Specifically, the null find-
ings support clinicians and patients in selecting either modality based
on availability, preferences, and other considerations. Althoughmelan-
cholic and atypical depression may be valid subtypes of depression,
there is no reason to assume that these patients respond differently
to CBT and ADM for depression in general.
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